CN106511665A - Pharmaceutical for treating allergic pneumonia - Google Patents

Pharmaceutical for treating allergic pneumonia Download PDF

Info

Publication number
CN106511665A
CN106511665A CN201611252790.8A CN201611252790A CN106511665A CN 106511665 A CN106511665 A CN 106511665A CN 201611252790 A CN201611252790 A CN 201611252790A CN 106511665 A CN106511665 A CN 106511665A
Authority
CN
China
Prior art keywords
parts
medicine
pneumonitiss
hypersensitivity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611252790.8A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Palm Network Technology Co Ltd
Original Assignee
Zhengzhou Palm Network Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Palm Network Technology Co Ltd filed Critical Zhengzhou Palm Network Technology Co Ltd
Priority to CN201611252790.8A priority Critical patent/CN106511665A/en
Publication of CN106511665A publication Critical patent/CN106511665A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8884—Arisaema, e.g. Jack in the pulpit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a pharmaceutical for treating allergic pneumonia, mainly prepared from, by weight, 8-15 parts of Arisaema cum Bile, 17-26 parts of root of Silene adenantha, 8-15 parts of Pterostilbene, 6-10 parts of saponins of Panax japonicus IVa, 11-16 parts of fraxinellone, 15-20 parts of ethyl palmitate, 6-10 parts of irinotecan, 30-40 parts of yejunualactone, 5-8 parts of tiliroside, 7-16 parts of purpurin, 2-6 parts of karanjin, and 5-9 parts of tetrahydrocoptisine. The materials for the pharmaceutical are selected strictly according to the understanding of the mechanism of allergic pneumonia so that full recovery is achieved; the pharmaceutical has the advantages that acting speed is high, action is stable, it is convenient to carry and administer, and the pharmaceutical has no toxic and side effects in long-term administration.

Description

A kind of medicine for treating hypersensitivity pneumonitiss
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of medicine for treating hypersensitivity pneumonitiss.
Background technology
Hypersensitivity pneumonitiss refer to various with antigenic organic dust, low-molecular-weight chemistry material etc. by sucking repeatedly Other anaphylactogens, so as to the swollen property pneumonopathy of the one group of diffusivity interstitial granulomatous dermatitis for causing.The generation of hypersensitivity pneumonitiss is mainly and season Property atmospheric pollution, indoor microorganism pollution it is relevant, the environment of etiology must be departed from before patient's treatment so as to breathe it is smooth simultaneously And cause the material of pulmonary abnormalities reaction without other in air.Common anaphylactogen mainly containing fungal spore, bacterial product, The Organic substance dust granules of animal protein or insecticide antigen, after suction anaphylactogen small number of patients occur pant, before watery nasal discharge etc. Phase symptom, started reaction symptom occur after 3～6 hours, was usually expressed as heating, dry cough, rapid breathing, chest pain and anoxia, mouth Lip, refer to toe end cyanosis etc., above-mentioned symptom reaches peak within 6～8 hours, and symptom disappears substantially within 24 hours, during outbreak physical signs of lung with Different during asthma attack, more without sound of stridulating, what is mainly heard is moist sound.Acute allergic pneumonia is often behind contact allergy source 4～8 hours fall ill, performance symptom be heating, fear of cold, cough, dyspnea, anorexia, nausea and vomiting, disengaging anaphylactogen it Afterwards, symptom typically improves within a few houres, but recovers completely to need several weeks, recurrent exerbation cause pulmonary fibrosiss；Subacute allergy Property symptoms of pneumonia outbreak it is slow, to several weeks, constantly development person needs hospitalization to the state of an illness for cough and dyspnea last for days；Slowly , generally there is dyspnea, cough, weak and weight loss up to the several months extremely after sexual activity is carried out in property hypersensitivity pneumonitiss patient Several years, severe patient can develop into respiratory failure, therefore early diagnosiss depart from the key institute of anaphylactogen treatment in time.Current medicine Thing treatment is mainly long-term steroid, can alleviate and eliminate Acute Exacerbation Period symptom, and can prevent permanent lesion such as bronchus The generation of expansion, irreversibility airway obstruction and pulmonary fibrosiss.But more importantly start to treat and prevent from the initial stage, therefore Need a kind of medicine play a part of to prevent and treat hypersensitivity pneumonitiss and can reduce for the infringement of human body pulmonary function.
The content of the invention
It is an object of the invention to provide a kind of medicine for treating hypersensitivity pneumonitiss, to solve to propose in above-mentioned background technology Problem.
For achieving the above object, the present invention provides following technical scheme：
A kind of medicine for treating hypersensitivity pneumonitiss, according to the primary raw material of weight portion be：Arisaema Cum Bile 8-15 parts, HEIQIANNIU 17-26 parts, pterostilbene 8-15 parts, Rhizoma Panacis Japonici saponin IVa 6-10 parts, ketone 11-16 parts, ethyl palmitate 15-20 parts, Yi Li For health 6-10 part, yejuhua lactone 30-40 parts, silver-colored Hibiscus syriacuss glycoside 5-8 parts, purpurin 7-16 parts, karanjin 2-6 parts, tetrahydrochysene Coptisine 5-9 parts.
As further scheme of the invention：The medicine of the treatment hypersensitivity pneumonitiss, according to the primary raw material of weight portion For：Arisaema Cum Bile 9-13 parts, HEIQIANNIU 19-22 part, pterostilbene 10-12 parts, Rhizoma Panacis Japonici saponin IVa 7-9 parts, ketone 12-14 parts, Ethyl palmitate 15-20 parts, irinotecan 6-10 parts, yejuhua lactone 34-37 parts, silver-colored Hibiscus syriacuss glycoside 5-8 parts, purpurin 7-16 Part, karanjin 3-4 parts, Tetrahydrocoptisine 5-9 parts.
As further scheme of the invention：The medicine of the treatment hypersensitivity pneumonitiss, according to the primary raw material of weight portion For：11 parts of Arisaema Cum Bile, 21 parts of HEIQIANNIU, 11 parts of pterostilbene, 8 parts of Rhizoma Panacis Japonici saponin IVa, 13 parts of ketone, ethyl palmitate 18 Part, 8 parts of irinotecan, 36 parts of yejuhua lactone, 7 parts of silver-colored Hibiscus syriacuss glycoside, 12 parts of purpurin, 4 parts of karanjin, Tetrahydrocoptisine 8 parts.
A kind of preparation method of the medicine for treating hypersensitivity pneumonitiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Arisaema Cum Bile, HEIQIANNIU, pterostilbene, Rhizoma Panacis Japonici saponin are weighed by above-mentioned metering ratio IVa, ketone, ethyl palmitate, irinotecan, yejuhua lactone, silver-colored Hibiscus syriacuss glycoside, purpurin, karanjin, tetrahydrochysene Rhizoma Coptidis Alkali, sieves, and machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 4-8min, controls RSD≤5%, after mixing Tabletting cold drying, at 4-8 DEG C, packaging obtains final product the medicine for the treatment of hypersensitivity pneumonitiss to temperature control.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention is strictly selected to material composition according to the understanding mechanism of hypersensitivity pneumonitiss, so as to reach comprehensively The purpose of rehabilitation, with rapid-action, effect it is stable, carry taking convenience, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described, Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention Embodiment, the every other embodiment obtained under the premise of creative work is not made by those of ordinary skill in the art, all Belong to the scope of protection of the invention.
Embodiment 1
A kind of medicine for treating hypersensitivity pneumonitiss, according to the primary raw material of weight portion be：8 parts of Arisaema Cum Bile, 17 parts of HEIQIANNIU, 8 parts of pterostilbene, 6 parts of Rhizoma Panacis Japonici saponin IVa, 11 parts of ketone, 15 parts of ethyl palmitate, 6 parts of irinotecan, yejuhua lactone 30 Part, 5 parts of silver-colored Hibiscus syriacuss glycoside, 7 parts of purpurin, 2 parts of karanjin, 5 parts of Tetrahydrocoptisine.
A kind of preparation method of the medicine for treating hypersensitivity pneumonitiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Arisaema Cum Bile, HEIQIANNIU, pterostilbene, Rhizoma Panacis Japonici saponin are weighed by above-mentioned metering ratio IVa, ketone, ethyl palmitate, irinotecan, yejuhua lactone, silver-colored Hibiscus syriacuss glycoside, purpurin, karanjin, tetrahydrochysene Rhizoma Coptidis Alkali, sieves, and machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 4min, control RSD≤5%, presses after mixing Piece cold drying, at 4 DEG C, packaging obtains final product the medicine for the treatment of hypersensitivity pneumonitiss to temperature control.
Embodiment 2
A kind of medicine for treating hypersensitivity pneumonitiss, according to the primary raw material of weight portion be：9 parts of Arisaema Cum Bile, 19 parts of HEIQIANNIU, 10 parts of pterostilbene, 7 parts of Rhizoma Panacis Japonici saponin IVa, 12 parts of ketone, 15 parts of ethyl palmitate, 6 parts of irinotecan, yejuhua lactone 34 Part, 5 parts of silver-colored Hibiscus syriacuss glycoside, 7 parts of purpurin, 3 parts of karanjin, 5 parts of Tetrahydrocoptisine.
A kind of preparation method of the medicine for treating hypersensitivity pneumonitiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Arisaema Cum Bile, HEIQIANNIU, pterostilbene, Rhizoma Panacis Japonici saponin are weighed by above-mentioned metering ratio IVa, ketone, ethyl palmitate, irinotecan, yejuhua lactone, silver-colored Hibiscus syriacuss glycoside, purpurin, karanjin, tetrahydrochysene Rhizoma Coptidis Alkali, sieves, and machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 4min, control RSD≤5%, presses after mixing Piece cold drying, at 4 DEG C, packaging obtains final product the medicine for the treatment of hypersensitivity pneumonitiss to temperature control.
Embodiment 3
A kind of medicine for treating hypersensitivity pneumonitiss, according to the primary raw material of weight portion be：11 parts of Arisaema Cum Bile, HEIQIANNIU 21 Part, 11 parts of pterostilbene, 8 parts of Rhizoma Panacis Japonici saponin IVa, 13 parts of ketone, 18 parts of ethyl palmitate, 8 parts of irinotecan, in Flos Chrysanthemi Indici 36 parts of ester, 7 parts of silver-colored Hibiscus syriacuss glycoside, 12 parts of purpurin, 4 parts of karanjin, 8 parts of Tetrahydrocoptisine.
A kind of preparation method of the medicine for treating hypersensitivity pneumonitiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Arisaema Cum Bile, HEIQIANNIU, pterostilbene, Rhizoma Panacis Japonici saponin are weighed by above-mentioned metering ratio IVa, ketone, ethyl palmitate, irinotecan, yejuhua lactone, silver-colored Hibiscus syriacuss glycoside, purpurin, karanjin, tetrahydrochysene Rhizoma Coptidis Alkali, sieves, and machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 6min, control RSD≤5%, presses after mixing Piece cold drying, at 6 DEG C, packaging obtains final product the medicine for the treatment of hypersensitivity pneumonitiss to temperature control.
Embodiment 4
A kind of medicine for treating hypersensitivity pneumonitiss, according to the primary raw material of weight portion be：13 parts of Arisaema Cum Bile, HEIQIANNIU 22 Part, 12 parts of pterostilbene, 9 parts of Rhizoma Panacis Japonici saponin IVa, 14 parts of ketone, 20 parts of ethyl palmitate, 10 parts of irinotecan, in Flos Chrysanthemi Indici 37 parts of ester, 8 parts of silver-colored Hibiscus syriacuss glycoside, 16 parts of purpurin, 4 parts of karanjin, 9 parts of Tetrahydrocoptisine.
A kind of preparation method of the medicine for treating hypersensitivity pneumonitiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Arisaema Cum Bile, HEIQIANNIU, pterostilbene, Rhizoma Panacis Japonici saponin are weighed by above-mentioned metering ratio IVa, ketone, ethyl palmitate, irinotecan, yejuhua lactone, silver-colored Hibiscus syriacuss glycoside, purpurin, karanjin, tetrahydrochysene Rhizoma Coptidis Alkali, sieves, and machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 8min, control RSD≤5%, presses after mixing Piece cold drying, at 8 DEG C, packaging obtains final product the medicine for the treatment of hypersensitivity pneumonitiss to temperature control.
Embodiment 5
A kind of medicine for treating hypersensitivity pneumonitiss, according to the primary raw material of weight portion be：15 parts of Arisaema Cum Bile, HEIQIANNIU 26 Part, 15 parts of pterostilbene, 10 parts of Rhizoma Panacis Japonici saponin IVa, 16 parts of ketone, 20 parts of ethyl palmitate, 10 parts of irinotecan, Flos Chrysanthemi Indici 40 parts of lactone, 8 parts of silver-colored Hibiscus syriacuss glycoside, 16 parts of purpurin, 6 parts of karanjin, 9 parts of Tetrahydrocoptisine.
A kind of preparation method of the medicine for treating hypersensitivity pneumonitiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Arisaema Cum Bile, HEIQIANNIU, pterostilbene, Rhizoma Panacis Japonici saponin are weighed by above-mentioned metering ratio IVa, ketone, ethyl palmitate, irinotecan, yejuhua lactone, silver-colored Hibiscus syriacuss glycoside, purpurin, karanjin, tetrahydrochysene Rhizoma Coptidis Alkali, sieves, and machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 8min, control RSD≤5%, presses after mixing Piece cold drying, at 8 DEG C, packaging obtains final product the medicine for the treatment of hypersensitivity pneumonitiss to temperature control.
Pharmacology test
1st, chronic toxicity test
With medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, the successive administration 2 times in the 24h, Per minor tick 8h, 400mg/kg doses are administered every time, daily accumulation medicine total amount reaches 800mg medicines/kg, it is clinical equivalent to people to use 100 times of amount.After administration in 7d, mice activity, feed, excretion are normal, well-grown, and hair color light, its average weight are equal Increase with the prolongation of experimental period.Every mice of post mortem at 8d, the perusal heart, liver, spleen, lung, kidney, brain, thymus, Stomach, intestinal etc. do not find color and paramophia, fail to measure median lethal dose(LD 50) (LD50).As a result show：Medicine of the present invention without Chronic toxicity.
2nd, long term toxicity test
With medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, medicine of the present invention is divided into into low dose Amount, middle dosage, three groups of high dose, the drug dose respectively 80,160,240mg medicines/kg/d of each group, equivalent to clinical dosage 10,20,30 times.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematological indices, blood biochemical Mark without significantly impact, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.Drug withdrawal 2 Also have no substantially change week.As a result show：Medicine of the present invention in long term toxicity test does not find overt toxicity reaction and postpones Toxic reaction.It can be seen that, medicine non-toxic reaction of the present invention, long-term prescription are safe and reliable.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be realized in other specific forms.Therefore, no matter From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped Containing an independent technical scheme, this narrating mode of description is only that those skilled in the art should for clarity Using description as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art Understandable other embodiment.

Claims (5)

1. a kind of medicine for treating hypersensitivity pneumonitiss, it is characterised in that the primary raw material according to weight portion is：Arisaema Cum Bile 8-15 Part, HEIQIANNIU 17-26 part, pterostilbene 8-15 parts, Rhizoma Panacis Japonici saponin IVa 6-10 parts, ketone 11-16 parts, ethyl palmitate 15- 20 parts, irinotecan 6-10 parts, yejuhua lactone 30-40 parts, silver-colored Hibiscus syriacuss glycoside 5-8 parts, purpurin 7-16 parts, karanjin 2- 6 parts, Tetrahydrocoptisine 5-9 parts.
2. it is according to claim 1 treatment hypersensitivity pneumonitiss medicine, it is characterised in that the treatment hypersensitivity pneumonitiss Medicine, according to the primary raw material of weight portion be：Arisaema Cum Bile 9-13 parts, HEIQIANNIU 19-22 part, pterostilbene 10-12 parts, Rhizoma Panacis Japonici soap Glycosides IVa 7-9 parts, ketone 12-14 parts, ethyl palmitate 15-20 parts, irinotecan 6-10 parts, yejuhua lactone 34-37 parts, silver Hibiscus syriacuss glycoside 5-8 parts, purpurin 7-16 parts, karanjin 3-4 parts, Tetrahydrocoptisine 5-9 parts.
3. it is according to claim 1 and 2 treatment hypersensitivity pneumonitiss medicine, it is characterised in that the treatment anaphylaxis lung Scorching medicine, according to the primary raw material of weight portion be：11 parts of Arisaema Cum Bile, 21 parts of HEIQIANNIU, 11 parts of pterostilbene, Rhizoma Panacis Japonici saponin 8 parts of IVa, 13 parts of ketone, 18 parts of ethyl palmitate, 8 parts of irinotecan, 36 parts of yejuhua lactone, 7 parts of silver-colored Hibiscus syriacuss glycoside, hydroxyl Radix Rubiae 12 parts of element, 4 parts of karanjin, 8 parts of Tetrahydrocoptisine.
4. a kind of preparation method of the medicine of the treatment hypersensitivity pneumonitiss as described in claim 1-3 is arbitrary, it is characterised in that tool Body step is：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh Arisaema Cum Bile, HEIQIANNIU, pterostilbene, Rhizoma Panacis Japonici saponin IVa, Ketone, ethyl palmitate, irinotecan, yejuhua lactone, silver-colored Hibiscus syriacuss glycoside, purpurin, karanjin, Tetrahydrocoptisine, mistake Sieve, machinery add ultra-pure water after mixing, and place in pharmacy mixer, mix 4-8min, control RSD≤5%, and after mixing, tabletting is simultaneously Cold drying, at 4-8 DEG C, packaging obtains final product the medicine for the treatment of hypersensitivity pneumonitiss to temperature control.
5. it is according to claim 4 treatment hypersensitivity pneumonitiss medicine preparation method, it is characterised in that in concrete steps Mixing 6min.
CN201611252790.8A 2016-12-30 2016-12-30 Pharmaceutical for treating allergic pneumonia Pending CN106511665A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611252790.8A CN106511665A (en) 2016-12-30 2016-12-30 Pharmaceutical for treating allergic pneumonia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611252790.8A CN106511665A (en) 2016-12-30 2016-12-30 Pharmaceutical for treating allergic pneumonia

Publications (1)

Publication Number Publication Date
CN106511665A true CN106511665A (en) 2017-03-22

Family

ID=58336187

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611252790.8A Pending CN106511665A (en) 2016-12-30 2016-12-30 Pharmaceutical for treating allergic pneumonia

Country Status (1)

Country Link
CN (1) CN106511665A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220395540A1 (en) * 2021-06-09 2022-12-15 Therapeutic Solutions International, Inc. Treatment of covid-19 lung injury using umbilical cord plasma based compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220395540A1 (en) * 2021-06-09 2022-12-15 Therapeutic Solutions International, Inc. Treatment of covid-19 lung injury using umbilical cord plasma based compositions

Similar Documents

Publication Publication Date Title
US8394423B2 (en) Compositions comprising apocynin, ginkgo and ginger and uses thereof
CN110548077A (en) Pharmaceutical composition for treating chronic pharyngitis and preparation method and application thereof
CN106511665A (en) Pharmaceutical for treating allergic pneumonia
CN105412281A (en) Traditional Chinese medicinal composition for treating allergic asthma and preparation method thereof
CN106727494A (en) A kind of Western medicine for treating Eaton agent pneumonia
CN106581032A (en) Western medicine for treating hylactic pneumonia
CN104840690A (en) Combination with auxiliary blood sugar and blood fat reduction effect
CN102188483B (en) Extract for treating pharyngolaryngitis and preparation method thereof
CN103417571A (en) Composition for treating chicken mycoplasma respiratory infection and preparing method thereof
CN106727650A (en) A kind of Western medicine for treating Eaton agent pneumonia
CN106728287A (en) A kind of Chinese and Western medicine combination for treating hylactic pneumonia and preparation method thereof
CN1329072C (en) Medicine for treating infant's fever and cough and preparing method
CN111588742A (en) Application of myrrh sesquiterpene extract in preparation of chronic obstructive pulmonary disease medicine
CN101732471B (en) Chinese medicinal composition having functions of clearing heat, detoxicating, eliminating phlegm and reliving cough
CN101829185B (en) Medicinal composition for resisting influenza virus
CN108186947A (en) A kind of Chinese medicine composition and its preparation method and application
CN106581031A (en) Compound Western medicine for treating pertussis
CN106619666A (en) Pharmaceutical composition for treating swine dysentery
CN106668599A (en) Drug for treating bronchiectasis
CN106727907A (en) A kind of Chinese and Western medicine combination for treating viral pneumonia and preparation method thereof
CN106668044A (en) Western medicine composition for treating chronic bronchitis
CN106491853A (en) A kind of Chinese medicine and western medicine combination for treating bronchiectasiss and preparation method thereof
Wang et al. Analysis of the Therapeutic Effect of Shengmai Yin Chinese Herbal Medicine in Pneumonia
Luo et al. Xiebai Zengye decoction improves respiratory function and attenuates inflammation in juvenile rats with postinfection cough via regulating ERK signaling pathway
CN106619686A (en) Western medicine for treating bronchiectasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170322

WD01 Invention patent application deemed withdrawn after publication